Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 5C12H22O11.C6H11O7.2Fe.Na.3O |
Molecular Weight | 2089.308 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 49 / 49 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[O--].[O--].[O--].[Na+].[Fe+3].[Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O.OC[C@H]3O[C@@](CO)(O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](O)[C@@H]3O.OC[C@H]5O[C@@](CO)(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)[C@@H](O)[C@@H]5O.OC[C@H]7O[C@@](CO)(O[C@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O)[C@@H](O)[C@@H]7O.OC[C@H]9O[C@@](CO)(O[C@H]%10O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%10O)[C@@H](O)[C@@H]9O
InChI
InChIKey=MQBDAEHWGRMADS-XNHLMZCASA-M
InChI=1S/5C12H22O11.C6H12O7.2Fe.Na.3O/c5*13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12;7-1-2(8)3(9)4(10)5(11)6(12)13;;;;;;/h5*4-11,13-20H,1-3H2;2-5,7-11H,1H2,(H,12,13);;;;;;/q;;;;;;2*+3;+1;3*-2/p-1/t5*4-,5-,6-,7-,8+,9-,10+,11-,12+;2-,3-,4+,5-;;;;;;/m111111....../s1
Molecular Formula | C6H8O7 |
Molecular Weight | 192.1235 |
Charge | -4 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | Fe |
Molecular Weight | 55.845 |
Charge | 3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C12H22O11 |
Molecular Weight | 342.2965 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | HO |
Molecular Weight | 17.0073 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.mfc.co.jp/english/eng/product/sanferol/pdf/fls_gras_notice.pdfhttps://mistralhowto.wordpress.com/2012/03/12/what-is-pigment-yellow-42-and-what-is-it-used-for/ | http://sensientfoodcolors.com/en-us/confection/iron-oxides-approved-by-the-fda/ | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=73.2250 | https://www.drugs.com/inactive/ferric-oxide-yellow-381.htmlhttps://books.google.ru/books?id=vxtxWneRBN4C&pg=PA1103v=onepage&q&f=falsehttps://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205874Orig1s000PharmR.pdfhttp://www.edta-chelate.com/ferric-ammonium-edta-liquid--1640836.htmlhttps://books.google.ru/books?id=3hLmyma2-MsC&pg=PA241&lpg=PA241&dq=FERRIC+AMMONIUM+CHLORIDE retrieved from A Consumer's Dictionary of Cosmetic Ingredients, 7th Edition: Complete Information About the Harmful and Desirable Ingredients Found in Cosmetics and Cosmeceuticals By Ruth Winterhttps://www.ncbi.nlm.nih.gov/pubmed/27995746 | http://onlinelibrary.wiley.com/doi/10.1002/047084289X.rn01568/abstract?userIsAuthenticated=false&deniedAccessCustomisedMessage=https://cameochemicals.noaa.gov/chemical/3468 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.ncbi.nlm.nih.gov/pubmed/27684194 | https://www.ncbi.nlm.nih.gov/pubmed/17511797 | https://www.ncbi.nlm.nih.gov/pubmed/1427505Curator's Comment: description was created based on several sources, including
https://www.gpo.gov/fdsys/pkg/CFR-1996-title21-vol3/pdf/CFR-1996-title21-vol3-sec182-5375.pdf
Sources: http://www.mfc.co.jp/english/eng/product/sanferol/pdf/fls_gras_notice.pdfhttps://mistralhowto.wordpress.com/2012/03/12/what-is-pigment-yellow-42-and-what-is-it-used-for/ | http://sensientfoodcolors.com/en-us/confection/iron-oxides-approved-by-the-fda/ | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=73.2250 | https://www.drugs.com/inactive/ferric-oxide-yellow-381.htmlhttps://books.google.ru/books?id=vxtxWneRBN4C&pg=PA1103v=onepage&q&f=falsehttps://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205874Orig1s000PharmR.pdfhttp://www.edta-chelate.com/ferric-ammonium-edta-liquid--1640836.htmlhttps://books.google.ru/books?id=3hLmyma2-MsC&pg=PA241&lpg=PA241&dq=FERRIC+AMMONIUM+CHLORIDE retrieved from A Consumer's Dictionary of Cosmetic Ingredients, 7th Edition: Complete Information About the Harmful and Desirable Ingredients Found in Cosmetics and Cosmeceuticals By Ruth Winterhttps://www.ncbi.nlm.nih.gov/pubmed/27995746 | http://onlinelibrary.wiley.com/doi/10.1002/047084289X.rn01568/abstract?userIsAuthenticated=false&deniedAccessCustomisedMessage=https://cameochemicals.noaa.gov/chemical/3468 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.ncbi.nlm.nih.gov/pubmed/27684194 | https://www.ncbi.nlm.nih.gov/pubmed/17511797 | https://www.ncbi.nlm.nih.gov/pubmed/1427505
Curator's Comment: description was created based on several sources, including
https://www.gpo.gov/fdsys/pkg/CFR-1996-title21-vol3/pdf/CFR-1996-title21-vol3-sec182-5375.pdf
Ferric chloride is a compound used as a food additive, a haemostatic or treatment for hypochromic anaemia. Ferric chloride induced vascular injury is a widely used model of occlusive thrombosis that reports platelet activation and aggregation in the context of an aseptic closed vascular system. Iron i.v. ferric chloride (960 mg) has being shown to be effective in correcting anaemia in HD patients with iron deficiency.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21121365 |
|||
Target ID: CHEMBL2364184 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Additrace N Approved UseA source of electrolytes and trace elements as an integral part of a complete intravenous nutritional regimen, for adults and
children over 40 kg. |
|||
Preventing | Parmirin Approved UsePreventive treatment of iron deficiency |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | SANFEROL Approved UseIt has also been reported that SFC preparation improved iron deficiency in a pregnant woman with iron deficiency anemia whose hemoglobin level had not increased after administration of other iron preparations such as ferrous fumarate. A dairy supplemental dose of SFC improved iron deficiency in young women with iron deficiency. |
|||
Inactive ingredient | Oxycontin Approved UseOxyContin is used in the treatment of chronic pain; pain and belongs to the drug class narcotic analgesics. Launch Date9.0935997E11 |
|||
Curative | RADIOGARDASE Approved UseInsoluble Prussian blue is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination. Launch Date1.06496642E12 |
|||
Palliative | AURYXIA Approved UseFerric Citrate is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. Launch Date1.40978881E12 |
PubMed
Title | Date | PubMed |
---|---|---|
[Effects of ferric fluoride compounds on dental enamel]. | 1954 Nov 15 |
|
Biological availability of iron supplements for rats, chicks and humans. | 1976 Feb |
|
Contact dermatitis to yellow iron oxide. | 1985 Aug |
|
Carcinogenicity studies on natural and man-made fibres with the intraperitoneal test in rats. | 1989 |
|
Effect of physical exercise and vitamin C on absorption of ferric sodium citrate. | 1996 Dec |
|
Non-invasive and non-destructive micro-XRF and micro-Raman analysis of a decorative wallpaper from the beginning of the 19th century. | 2007 Feb |
|
Interaction of omapatrilat with FD&C Blue No. 2 lake during dissolution of modified release tablets. | 2007 Jul 18 |
|
Oxidative aromatic C-N bond formation: convenient synthesis of N-amino-3-nitrile-indoles via FeBr3-mediated intramolecular cyclization. | 2011 May 21 |
|
FeF(3) catalyzed cascade C-C and C-N bond formation: synthesis of differentially substituted triheterocyclic benzothiazole functionalities under solvent-free condition. | 2014 May |
|
Nazarov cyclization of 1,4-pentadien-3-ols: preparation of cyclopenta[b]indoles and spiro[indene-1,4'-quinoline]s. | 2016 Feb 14 |
|
Mechanisms and origins of the switchable regioselectivity of FeBr3-catalyzed [1,2]-aryl and [1,2]-alkyl shifts of α-aryl aldehydes. | 2016 Feb 28 |
|
Halide Influence on Molecular and Supramolecular Arrangements of Iron Complexes with a 3,5-Bis(2-Pyridyl)-1,2,4,6-Thiatriazine Ligand. | 2016 Jun 6 |
|
Superior electrochemical performance of N-doped nanocrystalline FeF(3)/C with a single-step solid-state process. | 2016 Oct 4 |
|
Phosphorus recovery from biogas slurry by ultrasound/H(2)O(2) digestion coupled with HFO/biochar adsorption process. | 2017 Feb |
|
Effect of iron and carbon monoxide on fibrinogenase-like degradation of plasmatic coagulation by venoms of four Crotalus species. | 2017 Jan |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Iron oxides black, red and yellow are intended to be used as colourants in feedingstuffs for all animal species without dose or age restriction. The applicant recommends 500–1,200 mg/kg of the additives in complete (and complementary) feedingstuffs as standard dose. http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2016.4482/full
Ferric sodium citrate is an additive used in various foods such as baby milk powder, school and hospital food, beverages, cereals and supplements. It is administered orally.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:01:14 UTC 2023
by
admin
on
Fri Dec 15 16:01:14 UTC 2023
|
Record UNII |
CC9149U2QX
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000177913
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
||
|
NDF-RT |
N0000006237
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
||
|
NDF-RT |
N0000006237
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
||
|
NDF-RT |
N0000006237
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
34089-81-1
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
C77274
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
PRIMARY | |||
|
DB09517
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
PRIMARY | |||
|
CC9149U2QX
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
PRIMARY | |||
|
100000087402
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
PRIMARY | |||
|
Sodium Ferric Gluconate Complex
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
PRIMARY | |||
|
SUB13850MIG
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
PRIMARY | |||
|
SUB20743
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
PRIMARY | |||
|
DTXSID80187686
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
PRIMARY | |||
|
CHEMBL1201494
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
PRIMARY | |||
|
261435
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
PRIMARY | RxNorm | ||
|
KK-97
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
PRIMARY | |||
|
C1505
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
CONCEPT | Dietary Supplement | ||
|
Sodium ferric gluconate complex
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
PRIMARY | |||
|
CC9149U2QX
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
PRIMARY | |||
|
m10021
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
PRIMARY | Merck Index | ||
|
76968835
Created by
admin on Fri Dec 15 16:01:14 UTC 2023 , Edited by admin on Fri Dec 15 16:01:14 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |